Overactive bladder significantly affects quality of life.
about
Overactive bladder: strategies to ensure treatment compliance and adherencePersistence and compliance with medication management in the treatment of overactive bladderTranslational Research and Functional Changes in Voiding Function in Older AdultsOveractive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introductionAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachAssessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic dataCost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.Prevalence, evaluation and management of overactive bladder in primary careThe patient perspective on overactive bladder: a mixed-methods needs assessmentPumpkin Seed Oil Extracted From Cucurbita maxima Improves Urinary Disorder in Human Overactive BladderCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives.AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective studyImpact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile functionFluid manipulation among individuals with lower urinary tract symptoms: a mixed methods studyNGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndromeIncreased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapyA current perspective on geriatric lower urinary tract dysfunction.Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)Protein kinase C modulates frequency of micturition and non-voiding contractions in the urinary bladder via neuronal and myogenic mechanisms.The impact of overactive bladder on health-related quality of life, sexual life and psychological health in KoreaTobacco Stained Fingers and Its Association with Death and Hospital Admission: A Retrospective Cohort Study.Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study.Association between Menopausal Symptoms and Overactive Bladder: A Cross-Sectional Questionnaire Survey in ChinaA review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsRelationship between Body Mass Index and Overactive Bladder in Women and Correlations with Urodynamic Evaluation.Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in CanadaExperience with imidafenacin in the management of overactive bladder disorderA comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.A review of solifenacin in the treatment of urinary incontinence.Continuous positive airway pressure therapy is associated with improvement in overactive bladder symptoms in women with obstructive sleep apnea syndrome.Impact of Dry Mouth on Fluid Intake and Overactive Bladder Symptoms in Women taking Fesoterodine.Treatment of overactive bladder in the aging population: focus on darifenacin.Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experienceThe safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderlyActivation of bitter taste receptors (tas2rs) relaxes detrusor smooth muscle and suppresses overactive bladder symptomsSocial, economic, and health utility considerations in the treatment of overactive bladder.Characterization of overactive bladder in women in a primary care setting
P2860
Q26746914-99C1ABDA-1EA3-464C-A13D-396E0C60FFD3Q26765014-B1DDFB86-E0BB-4752-A58A-3B353BB79413Q26782134-BB7F02F7-038F-4A16-B6D2-F47C305F91C8Q27011502-97039E48-A172-457A-98FF-9C1B9B71114EQ28742444-D930EA7E-C977-4EF8-B787-313BA64BFCB3Q30891304-C546437D-F207-437B-BB7B-6B54FE8D033DQ31013378-68A83EFD-B82D-4711-9B9C-BA1B8C9EED96Q33402658-5509A4DF-D881-4642-B318-B8FF8B166A4CQ33647925-C9B816B8-2B74-4F39-9565-B39A9969CA6CQ33657667-EEE111EA-8EBE-40EB-A1F3-7E92D1095CEDQ33696642-C8153FDF-502D-4C8C-A344-3B928039DBC9Q33768707-8D3725CE-A59F-4AD3-86BB-6346B01DF340Q34112974-A0C23F37-9B8B-4AB2-B98E-E0D7F9B6B3A8Q34352604-DBDBFCA7-79B4-4DF6-AC33-242ADD844F0EQ34567905-4C11D3AD-BD92-4AEE-B695-FAD7F82D6E89Q34577433-B8B6FF66-04D0-4C14-985F-4B7B4F0DF5AEQ34774149-4AA0269F-E2A5-40D6-8C8B-B03391972600Q35009629-350481AF-DD4D-4693-8E3F-140064127212Q35348864-C12D1361-F4D9-4104-ABF4-84AD0107C401Q35419834-BC35CED6-86F5-4A3A-A7D7-56E62E67AC3CQ35532350-B946A60F-6194-43FC-A235-05F0AC70F9B5Q35539615-D3F3F877-4A23-4909-AC49-EA2D477F4EF9Q35777025-04D57D81-4F84-4D36-8ECD-947BC5828B7FQ36101488-95445EEA-A98A-4DE4-9130-AE2E0B351A1AQ36136905-AC46A098-E856-46DA-9912-AFE807E61161Q36307893-E51BA9A3-601A-4915-AD88-B3F9BEEBD567Q36313184-D284D3BB-59D0-47D7-9660-0C5499EA869BQ36326096-47B53331-B9CC-4418-9D6F-BC2E5EC928EEQ36541100-DD34F92B-C367-4B1C-B977-D9BE637D96FFQ36573702-C01CFE6E-79DA-4CF8-A120-F5C60B92E540Q36822864-3E21A279-BD9E-467F-8968-FA33C55C5922Q36840686-C015C86C-96D7-4D86-8B48-D2056975F247Q36963197-FBE24AA5-5875-466E-8FCE-739D6A9D0B75Q37018934-CF3951B1-2576-4FCA-819F-4453B3824590Q37114121-6681247A-8D68-4249-AC17-A27375623959Q37197554-EC08E0BB-6BE2-4338-98E8-240FD7F80C4CQ37199946-CC1373A0-3264-44F7-8A01-4448C705C251Q37225238-1DCB2707-385A-4E61-AB9C-4F2A2FAEE763Q37283547-172DA733-D1F5-4D87-8CAB-F7CB3594F11DQ37283712-A3396561-FF4A-4D72-A8BA-764479C5F389
P2860
Overactive bladder significantly affects quality of life.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Overactive bladder significantly affects quality of life.
@ast
Overactive bladder significantly affects quality of life.
@en
Overactive bladder significantly affects quality of life.
@nl
type
label
Overactive bladder significantly affects quality of life.
@ast
Overactive bladder significantly affects quality of life.
@en
Overactive bladder significantly affects quality of life.
@nl
prefLabel
Overactive bladder significantly affects quality of life.
@ast
Overactive bladder significantly affects quality of life.
@en
Overactive bladder significantly affects quality of life.
@nl
P2093
P1476
Overactive bladder significantly affects quality of life
@en
P2093
P304
P433
P577
2000-07-01T00:00:00Z